Overview
Bifidobacterium breve is a Gram-positive, anaerobic bacterium that serves as one of the earliest and most important colonizers of the infant gut. Among the first species to establish residence in the neonatal intestine, B. breve plays a critical role in immune system development, pathogen exclusion, and the establishment of a healthy microbiome foundation. While its abundance typically declines with age, it remains detectable in many adults and continues to exert beneficial effects throughout life.
The species has accumulated an extensive clinical evidence base, particularly for neonatal applications. Strain M-16V stands out as the most clinically studied infant Bifidobacterium strain, with over 36 clinical trials involving more than 4,000 infants, primarily focused on preventing necrotizing enterocolitis (NEC) in preterm neonates.
Classification
B. breve belongs to the family Bifidobacteriaceae within the phylum Actinomycetota (formerly Actinobacteria). It is a Gram-positive, non-motile, non-spore-forming, anaerobic rod-shaped bacterium with a characteristic Y-shaped bifid morphology. The species ferments a variety of carbohydrates through the fructose-6-phosphate phosphoketolase (F6PPK) pathway, producing primarily acetic acid and lactic acid. Reference genome strains include UCC2003 and JCM 7017.
Key Characteristics
B. breve is distinguished by its ability to rapidly colonize the infant intestine, where it may become a dominant member of the early gut microbiome. The species demonstrates strong adhesion to intestinal epithelial cells and produces antimicrobial compounds that help exclude potential pathogens. Strain Yakult (BBG-01), one of the earliest characterized strains, has been shown to reduce Campylobacter, Candida, and Enterococcus populations in the gut.
Certain strains also possess unique metabolic capabilities. BR03 is capable of oxalate degradation, which may contribute to reduced kidney stone risk, and produces conjugated linoleic acid (CLA), a fatty acid with potential anti-inflammatory and anti-cancer properties. The species also demonstrates strain-specific antimicrobial activity, with BR03 showing effectiveness against E. coli biotypes.
Health Significance
The health significance of B. breve is most firmly established in neonatal and pediatric medicine. Research indicates that M-16V supplementation may significantly reduce the incidence of NEC (stage II or higher) and infection rates in very low birth weight infants, with even short-term supplementation producing lasting shifts in microbiota composition toward bifidobacterial dominance. This has important implications for preterm infant care, where NEC remains a leading cause of morbidity and mortality.
Beyond neonatal applications, B. breve strains have shown promise in celiac disease management. Studies suggest that the combination of BR03 and B632 alongside a gluten-free diet may significantly reduce pro-inflammatory TNF-alpha levels in children with celiac disease. Additionally, strain MRx0004 has been investigated for severe asthma, demonstrating reduced neutrophil and eosinophil infiltration in preclinical models. These diverse applications reflect the species' broad immunomodulatory capacity across different age groups and clinical contexts.